The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography (Q36033077)

11 August 2017

1 reference

title

The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography (English)

1 reference

11 August 2017

main subject

X-ray crystallography

0 references

author name string

Adrian Gill

series ordinal

1

1 reference

11 August 2017

Anne Cleasby

series ordinal

2

1 reference

11 August 2017

Harren Jhoti

series ordinal

3

1 reference

11 August 2017

publication date

1 March 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

506-512

1 reference

Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Structural basis for control by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Structure−Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Protein kinase inhibitors: the tyrosine-specific protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Chemical inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Structural basis of inhibitor selectivity in MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Protein kinase inhibitors: insights into drug design from structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

New lead generation strategies for protein kinase inhibitors - fragment based screening approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Implications of protein flexibility for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

High-throughput crystallography for lead discovery in drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

High-throughput crystallography to enhance drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Discovering novel ligands for macromolecules using X-ray crystallographic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Requirements for Specific Binding of Low Affinity Inhibitor Fragments to the SH2 Domain ofpp60Src Are Identical to Those for High Affinity Binding of Full Length Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Structure-based screening of low-affinity compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Fragment-based lead discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Molecular complexity and its impact on the probability of finding leads for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Is there a difference between leads and drugs? A historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Molecular properties that influence the oral bioavailability of drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Computational methods for the prediction of 'drug-likeness'

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

A ‘Rule of Three’ for fragment-based lead discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Characterization of the structure and function of a novel MAP kinase kinase (MKK6)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Etanercept: a review of its use in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Etanercept: therapeutic use in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Cytokines in rheumatoid arthritis: trials and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

The non-diaryl heterocycle classes of p38 MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Pyridinylimidazole based p38 MAP kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

Current trends in lead discovery: are we looking for the appropriate properties?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200400188

21 January 2018

Identifiers

DOI

10.1002/CBIC.200400188

1 reference

11 August 2017

1 reference